Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes

Article Abstract:

An experimental drug called alefacept may be an effective treatment for psoriasis, according to a study of 229 patients. It is a recombinant protein that binds to and inactivates CD45RO+ memory effector T lymphocytes, which are believed to play a role in psoriasis.

---

Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial

Article Abstract:

Cyclosporine, an immunosuppressant drug often administered to organ transplant recipients, is also effective against some forms of psoriasis (a chronic skin disease involving plaques and scales). To learn more concerning the optimal dose of cyclosporine for treating this disorder, a 16-week controlled study of 85 patients was carried out. The patients had at least one fourth of their body surface covered by plaque-type psoriasis, or severe psoriasis that was disabling, and an unsatisfactory response to standard treatments for the disease (ultraviolet light or psoralen). Patients were randomly assigned to receive daily doses of 7.5 milligrams (15 patients), 5 milligrams (20 patients), or 3 milligrams (25 patients) of oral cyclosporine per kilogram of body weight. Twenty-five patients received an inactive drug (the control group). After the first eight weeks, patients who did not improve (including controls) were adjusted to the next higher dose (those at 7.5 mg/kg went up to 10 mg/kg). Three specific lesions on each patient were rated at regular intervals during the study for scaling, redness, plaque thickness, and overall severity. In addition, overall severity and extent of involvement of the body were rated. Kidney function (which is affected by cyclosporine in many people), blood pressure, white blood cell count, and other physiological variables were also evaluated. All patients who received cyclosporine improved more than patients who received the vehicle; for the three dose levels (from lowest to highest), the decrease in the psoriasis global scores was 39, 58, and 71 percent, respectively. The best effect was in the highest-dose group (80 percent clear or almost clear of lesions). Adjustments to higher doses were required for the largest proportion of patients in the lowest-dose group (65 percent). Four patients left the study because of side effects, and four required dose reduction. Effects on renal and neurologic function were noted. The results indicate that the best initial cyclosporine dose for treating plaque-type psoriasis is 5 milligrams per kilogram per day. Additional long-term studies are needed to evaluate the drug's safety and effectiveness. (Consumer Summary produced by Reliance Medical Information, Inc.)

Health aspects, Dosage and administration, Cyclosporine, Cyclosporins

---

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

Article Abstract:

A study was conducted to evaluate the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis. The therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis is demonstrated, and further evidence of a role of the interleukin-12/23 p40 cytokines in the pathophysiology of psoriasis is provided.

United States, HEALTH SERVICES, All Other Miscellaneous Ambulatory Health Care Services, Disease Testing Programs, Evaluation, Drugs, Interleukin-12, Drug evaluation, Clinical report

Similar abstracts:

• Abstracts: Relaxin causes proliferation of human amniotic epithelium by stimulation of insulin-like growth factor-II. Differentially expressed genes regulated by acute distention in amniotic epithelial (WISH) cells
• Abstracts: Enhancement of amniotic cyclooxygenase type 2 activity in women with preterm delivery associated with twins or polyhydramnios
• Abstracts: Accurate repair of the prolapsed vagina by use of measured lateral flaps. Vaginectomy with pelvic herniorrhaphy for prolapse
• Abstracts: The natural history of a positive response to transfundal pressure in women at risk for cervical incompetence
• Abstracts: Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.